PE20180949A1 - Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
PE20180949A1
PE20180949A1 PE2017002741A PE2017002741A PE20180949A1 PE 20180949 A1 PE20180949 A1 PE 20180949A1 PE 2017002741 A PE2017002741 A PE 2017002741A PE 2017002741 A PE2017002741 A PE 2017002741A PE 20180949 A1 PE20180949 A1 PE 20180949A1
Authority
PE
Peru
Prior art keywords
branched
group
straight
hydrogen atom
alkyl
Prior art date
Application number
PE2017002741A
Other languages
English (en)
Spanish (es)
Inventor
Zoltan Szlavik
Attila Paczal
Balazs Balint
Andras Kotschy
Maia Chanrion
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
Szabolcs Sipos
Agnes Proszenyak
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20180949A1 publication Critical patent/PE20180949A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PE2017002741A 2015-06-23 2016-06-22 Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen PE20180949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555753A FR3037958B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20180949A1 true PE20180949A1 (es) 2018-06-11

Family

ID=54260902

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002741A PE20180949A1 (es) 2015-06-23 2016-06-22 Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Country Status (46)

Country Link
US (1) US10322131B2 (enExample)
EP (1) EP3313849B8 (enExample)
JP (1) JP6773695B2 (enExample)
KR (1) KR102620976B1 (enExample)
CN (1) CN107922432B (enExample)
AR (1) AR105104A1 (enExample)
AU (1) AU2016282827B2 (enExample)
BR (1) BR112017027831A2 (enExample)
CA (1) CA2990083C (enExample)
CL (1) CL2017003316A1 (enExample)
CO (1) CO2017012845A2 (enExample)
CU (1) CU20170162A7 (enExample)
DK (1) DK3313849T3 (enExample)
DO (1) DOP2017000304A (enExample)
EA (1) EA036503B1 (enExample)
EC (1) ECSP17082825A (enExample)
ES (1) ES2944942T3 (enExample)
FI (1) FI3313849T3 (enExample)
FR (1) FR3037958B1 (enExample)
GE (2) GEP20207076B (enExample)
HK (1) HK1254477A1 (enExample)
HR (1) HRP20230472T1 (enExample)
HU (1) HUE061758T2 (enExample)
IL (1) IL256320A (enExample)
JO (1) JO3807B1 (enExample)
LT (1) LT3313849T (enExample)
MA (1) MA42231B1 (enExample)
MD (1) MD3313849T2 (enExample)
MX (1) MX385720B (enExample)
MY (1) MY190243A (enExample)
PE (1) PE20180949A1 (enExample)
PH (1) PH12017502314A1 (enExample)
PL (1) PL3313849T3 (enExample)
PT (1) PT3313849T (enExample)
PY (1) PY1638186A (enExample)
RS (1) RS64131B1 (enExample)
RU (1) RU2745430C9 (enExample)
SA (1) SA517390586B1 (enExample)
SI (1) SI3313849T1 (enExample)
SV (1) SV2017005590A (enExample)
TN (1) TN2017000529A1 (enExample)
TW (2) TWI715593B (enExample)
UA (1) UA124759C2 (enExample)
UY (1) UY36735A (enExample)
WO (1) WO2016207216A1 (enExample)
ZA (1) ZA201708626B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
EP3567043B1 (en) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
US10765680B2 (en) * 2017-01-06 2020-09-08 Les Laboratories Servier Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
UY37560A (es) * 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR112202A1 (es) * 2017-06-22 2019-10-02 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
WO2019101144A1 (zh) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
CN113024577B (zh) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 一种抗凋亡蛋白选择性抑制剂的制备方法
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
EP2139869A2 (en) * 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SA517390586B1 (ar) 2022-02-20
PH12017502314B1 (en) 2018-06-25
PH12017502314A1 (en) 2018-06-25
EP3313849B1 (en) 2023-02-22
SI3313849T1 (sl) 2023-07-31
NZ738469A (en) 2024-08-30
TN2017000529A1 (en) 2019-04-12
EP3313849B8 (en) 2023-05-10
JP6773695B2 (ja) 2020-10-21
TWI715593B (zh) 2021-01-11
HK1254477A1 (zh) 2019-07-19
PY1638186A (es) 2018-04-02
SV2017005590A (es) 2018-06-01
PT3313849T (pt) 2023-04-18
FR3037958A1 (enExample) 2016-12-30
MA42231B1 (fr) 2023-04-28
RU2745430C9 (ru) 2021-06-28
HK1250233A1 (zh) 2018-12-07
US20180185369A1 (en) 2018-07-05
DK3313849T3 (da) 2023-05-30
BR112017027831A2 (pt) 2018-09-04
DOP2017000304A (es) 2018-02-28
GEP20207076B (en) 2020-03-10
MY190243A (en) 2022-04-07
ES2944942T3 (es) 2023-06-27
FI3313849T3 (fi) 2023-05-11
IL256320A (en) 2018-02-28
EA036503B1 (ru) 2020-11-17
CA2990083C (en) 2021-05-25
MA42231A (fr) 2018-05-02
LT3313849T (lt) 2023-05-10
PL3313849T3 (pl) 2023-07-10
UA124759C2 (uk) 2021-11-17
CA2990083A1 (en) 2016-12-29
CN107922432B (zh) 2021-05-04
EA201890124A1 (ru) 2018-05-31
WO2016207216A1 (en) 2016-12-29
MD3313849T2 (ro) 2023-07-31
UY36735A (es) 2016-12-30
HUE061758T2 (hu) 2023-08-28
GEAP201914680A (en) 2019-11-11
RU2745430C1 (ru) 2021-03-25
TW201712019A (zh) 2017-04-01
HRP20230472T1 (hr) 2023-07-21
AR105104A1 (es) 2017-09-06
CN107922432A (zh) 2018-04-17
CU20170162A7 (es) 2018-06-05
AU2016282827B2 (en) 2020-07-09
ECSP17082825A (es) 2018-02-28
US10322131B2 (en) 2019-06-18
MX2017017008A (es) 2018-08-15
RS64131B1 (sr) 2023-05-31
JP2018527296A (ja) 2018-09-20
AU2016282827A1 (en) 2018-01-18
CO2017012845A2 (es) 2018-03-28
KR20180015263A (ko) 2018-02-12
FR3037958B1 (fr) 2019-01-25
MX385720B (es) 2025-03-18
KR102620976B1 (ko) 2024-01-05
TW202108590A (zh) 2021-03-01
CL2017003316A1 (es) 2018-04-27
EP3313849A1 (en) 2018-05-02
ZA201708626B (en) 2022-06-29
JO3807B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
PE20180949A1 (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20180742A1 (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20181491A1 (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20200700A1 (es) Compuestos macrociclicos y usos de los mismos
CL2020001546A1 (es) Compuestos de 4-azaindol.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
AR109315A1 (es) Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
PE20160931A1 (es) Macrociclos de diarilo como moduladores de la proteina quinasa
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
MX2016000904A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
MX2013008750A (es) Analogos de estilbeno y metodos para tratar cancer.
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
CU24380B1 (es) Derivados de 3- [2- (3,4-dihidroisoquinolin-2 (1 h) -ilcarbonil) fenil] -n- (4-hidroxifenil) -n-fenil-5,6,7,8 - tetrahidroindolizina -1-carboxamida útiles como inhibidores bcl-2 antiapoptóticos, y composiciones farmacéuticas que los contienen
ECSP17069696A (es) Compuestos novedosos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
PE20201498A1 (es) Nuevos derivados macrociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen